Equity Profile

COLL

Collegium Pharmaceutical, Inc.

Health CarePharmaceuticals$1.1B

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Collegium Pharmaceutical, Inc. is a healthcare company focused on developing and commercializing innovative pain management solutions....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and performance, which investors closely monitor.

Not available

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and drive sales, which is crucial for future investments.

Not available

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

COLL Q2-2026 Earnings Preview

Context

Company Snapshot

Collegium Pharmaceutical, Inc. is a healthcare company focused on developing and commercializing innovative pain management solutions. With a market cap of $1 billion, it plays a significant role in the pharmaceuticals sector, particularly in addressing the needs of patients with chronic pain.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+18.86%

Avg Stock Reaction

+4.02%

Last Quarter Recap

In Q1-2026, Collegium reported an EPS of $1.76, significantly surpassing estimates by 43%. The stock reacted positively, gaining 7.72% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic ahead of the earnings report, given Collegium's strong track record of beating EPS estimates. However, there is uncertainty regarding revenue figures and overall market conditions.

Bull Case

If Collegium continues its trend of surpassing EPS expectations, it could signal robust demand for its products and lead to a strong stock performance.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could raise concerns about its growth trajectory and negatively impact the stock.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

Given Collegium's history of exceeding EPS estimates, this figure will be crucial for market sentiment and stock performance.

How is Collegium's revenue growth tracking in the current market?

Revenue growth is essential for understanding the company's operational health and future prospects, especially in a competitive industry.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Collegium's ability to maintain its growth trajectory despite market challenges, especially given its strong historical performance.

Supporting Evidence

Collegium has consistently beaten EPS estimates, suggesting a stronger operational performance than anticipated.

The options market is pricing in a significant move, indicating that investors expect volatility and potential positive surprises.

Key Risk

If EPS comes in below $1.50, it could challenge the current positive sentiment and lead to a reevaluation of growth expectations.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on Collegium's ability to sustain its growth momentum and profitability in a challenging market.

Bull Confirmed If

An EPS of $1.80 or higher would confirm the bull case, indicating strong demand and effective cost management.

Bear Confirmed If

An EPS below $1.50 would suggest potential challenges in maintaining profitability and could confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±11.94%

Historical Avg

±4.9%

Pricing rich

The options market is pricing in a significant move, suggesting that investors anticipate volatility around the earnings announcement.

Options are pricing ±11.9% while COLL has averaged ±4.9% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

39.8%

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Collegium beats expectations, history suggests a potential stock increase of around 4.02%, confirming strong demand and operational efficiency.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further guidance.

Miss

A miss on EPS could lead to a decline, with historical data suggesting a potential drop of around 4.02%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or market expansions.
2Insights into cost management strategies and their impact on margins.
3Comments on competitive pressures in the pain management sector.
4Guidance on revenue expectations for the next quarter.
5Any changes in regulatory environment affecting the business.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Collegium Pharmaceutical, Inc. is a healthcare company focused on developing and commercializing innovative pain management solutions....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and performance, which investors closely monitor.

Not available

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and drive sales, which is crucial for future investments.

Not available

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

COLL Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+18.86%

Avg Stock Reaction

+4.02%

Last Quarter Recap

In Q1-2026, Collegium reported an EPS of $1.76, significantly surpassing estimates by 43%. The stock reacted positively, gaining 7.72% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Collegium continues its trend of surpassing EPS expectations, it could signal robust demand for its products and lead to a strong stock performance.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could raise concerns about its growth trajectory and negatively impact the stock.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

Given Collegium's history of exceeding EPS estimates, this figure will be crucial for market sentiment and stock performance.

How is Collegium's revenue growth tracking in the current market?

Revenue growth is essential for understanding the company's operational health and future prospects, especially in a competitive industry.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Collegium's ability to maintain its growth trajectory despite market challenges, especially given its strong historical performance.

Supporting Evidence

Collegium has consistently beaten EPS estimates, suggesting a stronger operational performance than anticipated.

The options market is pricing in a significant move, indicating that investors expect volatility and potential positive surprises.

Key Risk

If EPS comes in below $1.50, it could challenge the current positive sentiment and lead to a reevaluation of growth expectations.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on Collegium's ability to sustain its growth momentum and profitability in a challenging market.

Bull Confirmed If

An EPS of $1.80 or higher would confirm the bull case, indicating strong demand and effective cost management.

Bear Confirmed If

An EPS below $1.50 would suggest potential challenges in maintaining profitability and could confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±11.94%

Historical Avg

±4.9%

Pricing rich

The options market is pricing in a significant move, suggesting that investors anticipate volatility around the earnings announcement.

Options are pricing ±11.9% while COLL has averaged ±4.9% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

39.8%

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Collegium beats expectations, history suggests a potential stock increase of around 4.02%, confirming strong demand and operational efficiency.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further guidance.

Miss

A miss on EPS could lead to a decline, with historical data suggesting a potential drop of around 4.02%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or market expansions.
2Insights into cost management strategies and their impact on margins.
3Comments on competitive pressures in the pain management sector.
4Guidance on revenue expectations for the next quarter.
5Any changes in regulatory environment affecting the business.